» Articles » PMID: 32943423

Quantifying Intra-Arterial Verapamil Response As a Diagnostic Tool for Reversible Cerebral Vasoconstriction Syndrome

Overview
Specialty Neurology
Date 2020 Sep 18
PMID 32943423
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: There is mounting evidence supporting the benefit of intra-arterial administration of vasodilators in diagnosing reversible cerebral vasoconstriction syndrome. We prospectively quantified the degree of luminal diameter dilation after intra-arterial administration of verapamil and its accuracy in diagnosing reversible cerebral vasoconstriction syndrome.

Materials And Methods: Patients suspected of having intracranial arteriopathy on noninvasive imaging and referred for digital subtraction angiography were enrolled in a prospective registry. Intra-arterial verapamil was administered in vascular territories with segmental irregularities. The caliber difference (Caliber - Caliber) and the proportion of caliber change ([(Caliber - Caliber)/Caliber] × 100%) were used to determine the response to verapamil. The diagnosis of reversible cerebral vasoconstriction syndrome was made on the basis of clinical and imaging features at a follow-up appointment, independent of the reversibility of verapamil. Receiver operating characteristic curve analysis was performed to determine the best threshold.

Results: Twenty-six patients were included, and 9 (34.6%) were diagnosed with reversible cerebral vasoconstriction syndrome. A total of 213 vascular segments were assessed on diagnostic angiography. Every patient with a final diagnosis of reversible cerebral vasoconstriction syndrome responded to intra-arterial verapamil. The maximal proportion of change (< .001), mean proportion of change (= .002), maximal caliber difference (= .004), and mean caliber difference (= .001) were statistically different between patients with reversible cerebral vasoconstriction syndrome and other vasculopathies. A maximal proportion of change  ≥32% showed a sensitivity of 100% and a specificity of 88.2% to detect reversible cerebral vasoconstriction syndrome (area under the curve = 0.951). The Reversible Cerebral Vasoconstriction Syndrome-2 score of  ≥5 points achieved a lower area under the curve (0.908), with a sensitivity of 77.8% and a specificity of 94.1%.

Conclusions: Objective measurement of the change in the arterial calibers after intra-arterial verapamil is accurate in distinguishing reversible cerebral vasoconstriction syndrome from other vasculopathies. A proportion of change  ≥32% has the best diagnostic performance.

Citing Articles

Reversible Cerebral Vasoconstriction Syndrome Secondary to Escitalopram.

Postolowski M, Shakil O, Ramachandran L, Rao C Clin Med Res. 2025; 22(4):222-226.

PMID: 39993827 PMC: 11849965. DOI: 10.3121/cmr.2025.1864.


Glue embolization of ruptured pseudoaneurysm secondary to reversible cerebral vasoconstriction syndrome: An illustrative case.

Tshibangu M, McGuire L, Theiss P, Alaraj A Interv Neuroradiol. 2024; :15910199241251907.

PMID: 38748537 PMC: 11577156. DOI: 10.1177/15910199241251907.


Intra-arterial application of nimodipine in reversible cerebral vasoconstriction syndrome: a neuroradiological method to help differentiate from primary central nervous system vasculitis.

Strunk D, Veltkamp R, Meuth S, Chapot R, Kraemer M Neurol Res Pract. 2022; 4(1):8.

PMID: 35227319 PMC: 8883624. DOI: 10.1186/s42466-022-00173-0.

References
1.
Farid H, Tatum J, Wong C, Halbach V, Hetts S . Reversible cerebral vasoconstriction syndrome: treatment with combined intra-arterial verapamil infusion and intracranial angioplasty. AJNR Am J Neuroradiol. 2011; 32(10):E184-7. PMC: 7966008. DOI: 10.3174/ajnr.A2341. View

2.
Linn J, Fesl G, Ottomeyer C, Straube A, Dichgans M, Bruckmann H . Intra-arterial application of nimodipine in reversible cerebral vasoconstriction syndrome: a diagnostic tool in select cases?. Cephalalgia. 2011; 31(10):1074-81. DOI: 10.1177/0333102410394673. View

3.
Miller T, Shivashankar R, Mossa-Basha M, Gandhi D . Reversible Cerebral Vasoconstriction Syndrome, Part 2: Diagnostic Work-Up, Imaging Evaluation, and Differential Diagnosis. AJNR Am J Neuroradiol. 2015; 36(9):1580-8. PMC: 7968777. DOI: 10.3174/ajnr.A4215. View

4.
Calabrese L, Dodick D, Schwedt T, Singhal A . Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007; 146(1):34-44. DOI: 10.7326/0003-4819-146-1-200701020-00007. View

5.
Singhal A, Topcuoglu M . Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology. 2016; 88(3):228-236. PMC: 5272793. DOI: 10.1212/WNL.0000000000003510. View